Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102

06.05.2022 - SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates.The study met its ...

Related Keywords

California , United States , New York , Illinois , San Diego , University Of Illinois At Chicago , Palo Alto , Jaisim Shah , Brian Cooley , Nebojsa Nick Knezevic , Jeffrey Chi , Deyo Weinstein , Decisions Resources Group , Semnur Pharmaceuticals Inc , Vickers Vantage Corp , American Society Of Neuromodulation , Department Of Anesthesiology , Nasdaq , Scilex Holding Company , Pivotal Trialc Le Ar Program , Scilex Pharmaceuticals Inc , College Of Medicine , Company Or Scilex , Illinois Society Of Interventional Pain Physicians , Illinois Masonic Medical Center , Practice Research Clinical Rheumatology , Drug Administration , Sorrento Therapeutics Inc , Sorrento Company , Corporate Communications , Presenting Author , Illinois Society , Interventional Pain Physicians , North American Society , Advocate Illinois Masonic Medical Center , Innovation Summit , Holding Company , Sorrento Therapeutics , Lumbar Epidural Analgesia , Text View , Combined Company , Securities Act , Private Securities Litigation Reform Act , Nasdaq Capital Market , Media Contact , Lymphatic Drug , Nicolette Ten , Senior Account Executive , Semnur Pharmaceuticals , Scilex Holding , All Rights , Research Clinical , Chronic Pain , Disease Landscape ,